Shuntaro Kodama

Managing Director
DCI Partners Co., Ltd.
​​

Joined NIF Ventures (now known as Daiwa Corporate Investment, "DCI") in 2005. Mr. Kodama was responsible for domestic and overseas investments in biopharmaceutical companies at NIF. In 2014, the life science team was spun off from DCI and established a new VC firm called DCI Partners. DCI Partners is a leading Japanese venture capital firm dedicated to life sciences and now has over JPY 26 billion in AUM across 2 funds. He is an initial member as well as an investment committee member of DCI Partners. He has nearly 20 years' VC investment career and is currently serving on the board of directors for multiple portfolio companies in Japan and Taiwan.

Speech title & Synopsis

Investment strategy leveraging Taiwan-Japan collaboration

DCI Partners (“DCIP”) is fully dedicated to Life Sciences and managing funds supported by a wide variety of Japanese and Taiwanese collaborators. DCIP is quite active on Venture Creation model which is creating companies by in-licensing assets from pharmas, biotechs and academics.
DCIP aims for add-value investments by leveraging the two countries’ strengths with venture creation skillset, and some case studies for Taiwan-Japan collaboration and Venture Creation model are introduced.